StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Top 3 Wholesalers Combined by Year

Top 3 Wholesalers Combined — Share of U.S. Gross Product Sales (legacy disclosure) (%) (%)

Amgen Top 3 Wholesalers Combined: 98.0% in FY2018, up 2.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2018
98.0%
Period ended Dec 31, 2018
Change on a year earlier
+2.0 pts
96.0% in FY2017
History
4 years
Since FY2015
Sources
4
Documents cited below

Where the FY2018 figure comes from

Source: Form 10-K (filed 2019-02-13) ↗

Reported in Form 10-K Note 1 Customer Concentration (XBRL).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTop 3 Wholesalers Combined — Share of U.S. Gross Product Sales (legacy disclosure) (%) (%)Year on yearSource
FY2018Dec 31, 201898.0%+2.0 ptsForm 10-K (filed 2019-02-13) ↗
FY2017Dec 31, 201796.0%0.0 ptsForm 10-K (filed 2018-02-13) ↗
FY2016Dec 31, 201696.0%-1.0 ptsForm 10-K (filed 2017-02-14) ↗
FY2015Dec 31, 201597.0%–Form 10-K (filed 2016-02-16) ↗

Cite this data

StockData. (2026). Amgen Top 3 Wholesalers Combined (%), annual FY2015–FY2018 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/conc-top3-us-pct

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.